Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically...
67 KB (5,895 words) - 12:08, 7 May 2024
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin)...
25 KB (2,085 words) - 03:15, 6 July 2024
Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin)...
29 KB (2,699 words) - 00:43, 10 February 2024
Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast...
12 KB (966 words) - 04:46, 15 July 2024
antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is...
43 KB (4,651 words) - 05:18, 13 July 2024
Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing...
11 KB (703 words) - 18:13, 27 March 2024
brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer;...
24 KB (2,275 words) - 00:45, 12 July 2024
authorization from the European Medicines Agency in October 2012. Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech...
40 KB (4,270 words) - 13:46, 14 July 2024
2021. Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable...
21 KB (1,683 words) - 18:47, 17 March 2024
of camptothecin with antineoplastic activity. A derivative is used in Trastuzumab deruxtecan. Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz...
3 KB (98 words) - 05:18, 1 January 2024
aspart, insulin glargine, pegfilgrastim, rituximab, teriparatide, and trastuzumab. A research article about "Maximizing the benefits of using biosimilars...
95 KB (6,480 words) - 22:51, 13 May 2024
(Rituxan Hycela), trastuzumab/hyaluronidase-oysk (Herceptin Hylecta), daratumumab/hyaluronidase-fihj (Darzalex Faspro), and pertuzumab/trastuzumab/hyaluronidase–zzxf...
31 KB (2,895 words) - 10:05, 2 June 2024
Uterine serous carcinoma (section Trastuzumab)
antibody trastuzumab (Herceptin) is currently being tested as a therapy for this subset of uterine serous carcinomas. The antibody trastuzumab (Herceptin)...
10 KB (1,197 words) - 17:13, 13 June 2024
create an antibody-drug conjugate (ADC). ADCs with this design include trastuzumab emtansine, lorvotuzumab mertansine, and cantuzumab mertansine. Some are...
6 KB (471 words) - 09:43, 12 February 2024
HER2-targeted antibody trastuzumab to chemotherapy reduces the chance of cancer recurrence and death by at least a third. Trastuzumab is given weekly or every...
129 KB (14,628 words) - 14:31, 8 July 2024
example, a targeted anticancer agent – trastuzumab emtansine (antibody-drug conjugate containing an antibody trastuzumab chemically linked to a highly potent...
2 KB (97 words) - 22:42, 6 February 2024
Kadcyla (ado-trastuzumab emtansine): The first Genentech antibody-drug conjugate (ADC) to receive FDA approval. It consists of trastuzumab (Herceptin)...
38 KB (3,369 words) - 17:52, 24 May 2024
Isatuximab L01FD01 Trastuzumab L01FD02 Pertuzumab L01FD03 Trastuzumab emtansine L01FD04 Trastuzumab deruxtecan L01FD05 Trastuzumab duocarmazine L01FD06...
12 KB (877 words) - 15:36, 25 January 2024
antibody treatments, notably for lymphoma (Rituximab) and breast cancer (Trastuzumab). Vaccines and other immunotherapies are the subject of intensive research...
24 KB (2,589 words) - 20:56, 22 May 2024
other cardiotoxic chemotherapy drugs, such as trastuzumab. There is an FDA black box warning that trastuzumab cannot be used in concurrent combination with...
48 KB (4,385 words) - 13:38, 11 January 2024
monoclonal antibody (mAb) approved by the EMA. Herzuma is a biosimilar trastuzumab approved by the MFDS for treatment of early and advanced (metastatic)...
10 KB (672 words) - 09:09, 10 April 2024
proteins to activate the NK cell. The effects against solid tumors of trastuzumab and rituximab monoclonal antibodies have been shown in experiments with...
13 KB (1,661 words) - 22:18, 9 December 2023
Sankyo.” This list is not comprehensive. Oncology Enhertu (trastuzumab deruxtecan, fam-trastuzumab deruxtecan-nxki in the United States only) Ezharmia (valemetostat)...
29 KB (2,326 words) - 13:59, 3 May 2024
Cancer Institute. He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers. Pivot was born on April 20, 1967, in...
11 KB (1,127 words) - 17:13, 3 December 2023
Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib Lapatinib...
121 KB (13,799 words) - 06:42, 1 July 2024
lymphocytic leukaemia. Hemlibra (emicizumab), for haemophilia A. Herceptin (trastuzumab), for HER-2 positive breast cancer. Hivid (zalcitabine), for HIV-1 infection...
57 KB (5,236 words) - 09:00, 28 June 2024
likely to respond to treatment. Because the breast cancer medication trastuzumab is known to target protein HER2, for example, tumors can be screened...
17 KB (1,851 words) - 04:52, 27 May 2024
Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib Lapatinib...
31 KB (3,413 words) - 23:30, 21 June 2024
and the efficacy of targeted therapy against the Her-2 receptor with trastuzumab (Herceptin) in the treatment of adenocarcinomas at the gastroesophageal...
41 KB (4,311 words) - 01:35, 4 July 2024
to specific monoclonal antibody (antibody–drug conjugate), such as: Trastuzumab deruxtecan. It is licensed for the treatment of breast cancer or gastric...
10 KB (586 words) - 14:33, 26 March 2024